BACKGROUND: Brain imaging studies suggest that volume reductions and compromised white matter integrity occur in schizophrenia and bipolar disorder (BD). However, the cellular correlates have not yet been identified. To address this issue we assessed oligodendrocyte, astrocyte and microglial populations in postmortem white matter from schizophrenia, BD and nonpsychiatric control samples. METHODS: The density, areal fraction and spatial distribution of glial fibrillary acidic protein (GFAP)-expressing astrocytes and ionized calcium-binding adaptor molecule-1 (IBA-1)-expressing microglia as well as the density, nuclear size and spatial distribution of Nissl-stained oligodendrocytes were quantified in postmortem white matter adjacent to the dorsolateral prefrontal cortex (Brodmann area 9) in schizophrenia, BD and control samples (n = 20). In addition, the oligodendrocyte-associated proteins myelin basic protein and 2,3-cyclic-nucleotide 3-phosphodiesterase (CNPase) were quantified in the same samples by enzyme-linked immunosorbent assay and immunoblotting. RESULTS: Oligodendrocyte density (p = 0.012) and CNPase protein levels (p = 0.038) differed between groups, being increased in BD compared with control samples. The GFAP area fraction (p = 0.05) and astrocyte spatial distribution (p = 0.040) also differed between groups, reflecting decreased area fraction and increased cell clustering in both schizophrenia and BD samples. LIMITATIONS: Oligodendrocytes were identified using morphological criteria. CONCLUSION: This study provides evidence for glial pathology in prefrontal white matter in schizophrenia and BD. Changes in oligodendrocyte and astrocyte populations in white matter in the major psychiatric disorders may reflect disruptions in structural or metabolic support of axons.
BACKGROUND: Brain imaging studies suggest that volume reductions and compromised white matter integrity occur in schizophrenia and bipolar disorder (BD). However, the cellular correlates have not yet been identified. To address this issue we assessed oligodendrocyte, astrocyte and microglial populations in postmortem white matter from schizophrenia, BD and nonpsychiatric control samples. METHODS: The density, areal fraction and spatial distribution of glial fibrillary acidic protein (GFAP)-expressing astrocytes and ionizedcalcium-binding adaptor molecule-1 (IBA-1)-expressing microglia as well as the density, nuclear size and spatial distribution of Nissl-stained oligodendrocytes were quantified in postmortem white matter adjacent to the dorsolateral prefrontal cortex (Brodmann area 9) in schizophrenia, BD and control samples (n = 20). In addition, the oligodendrocyte-associated proteins myelin basic protein and 2,3-cyclic-nucleotide 3-phosphodiesterase (CNPase) were quantified in the same samples by enzyme-linked immunosorbent assay and immunoblotting. RESULTS: Oligodendrocyte density (p = 0.012) and CNPase protein levels (p = 0.038) differed between groups, being increased in BD compared with control samples. The GFAP area fraction (p = 0.05) and astrocyte spatial distribution (p = 0.040) also differed between groups, reflecting decreased area fraction and increased cell clustering in both schizophrenia and BD samples. LIMITATIONS: Oligodendrocytes were identified using morphological criteria. CONCLUSION: This study provides evidence for glial pathology in prefrontal white matter in schizophrenia and BD. Changes in oligodendrocyte and astrocyte populations in white matter in the major psychiatric disorders may reflect disruptions in structural or metabolic support of axons.
Authors: S G Fillman; N Cloonan; V S Catts; L C Miller; J Wong; T McCrossin; M Cairns; C S Weickert Journal: Mol Psychiatry Date: 2012-08-07 Impact factor: 15.992
Authors: Hans-Gert Bernstein; Karl-Heinz Smalla; Diana Dürrschmidt; Gerburg Keilhoff; Henrik Dobrowolny; Johann Steiner; Andrea Schmitt; Michael R Kreutz; Bernhard Bogerts Journal: Neuromolecular Med Date: 2012-06-19 Impact factor: 3.843
Authors: Pavel Katsel; Kenneth L Davis; Celeste Li; Weilun Tan; Elizabeth Greenstein; Lisa B Kleiner Hoffman; Vahram Haroutunian Journal: Neuropsychopharmacology Date: 2008-03-05 Impact factor: 7.853
Authors: Natalya A Uranova; Victor M Vostrikov; Diana D Orlovskaya; Valentina I Rachmanova Journal: Schizophr Res Date: 2004-04-01 Impact factor: 4.939
Authors: Benjamin J S Al-Haddad; Elizabeth Oler; Blair Armistead; Nada A Elsayed; Daniel R Weinberger; Raphael Bernier; Irina Burd; Raj Kapur; Bo Jacobsson; Caihong Wang; Indira Mysorekar; Lakshmi Rajagopal; Kristina M Adams Waldorf Journal: Am J Obstet Gynecol Date: 2019-06-15 Impact factor: 8.661
Authors: L E Laskaris; M A Di Biase; I Everall; G Chana; A Christopoulos; E Skafidas; V L Cropley; C Pantelis Journal: Br J Pharmacol Date: 2016-01-08 Impact factor: 8.739
Authors: Ronald Kim; Kati L Healey; Marian T Sepulveda-Orengo; Kathryn J Reissner Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2017-10-06 Impact factor: 5.067